Specialty Retail
Compare Stocks
2 / 10Stock Comparison
YSG vs SKIN
Revenue, margins, valuation, and 5-year total return — side by side.
Household & Personal Products
YSG vs SKIN — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Specialty Retail | Household & Personal Products |
| Market Cap | $299M | $118M |
| Revenue (TTM) | $4.07B | $296M |
| Net Income (TTM) | $-479M | $-6M |
| Gross Margin | 78.3% | 64.9% |
| Operating Margin | -3.9% | -3.6% |
| Forward P/E | 5.1x | — |
| Total Debt | $149M | $379M |
| Cash & Equiv. | $817M | $233M |
YSG vs SKIN — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Nov 20 | May 26 | Return |
|---|---|---|---|
| Yatsen Holding Limi… (YSG) | 100 | 3.5 | -96.5% |
| The Beauty Health C… (SKIN) | 100 | 9.0 | -91.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: YSG vs SKIN
Each card shows where this stock fits in a portfolio — not just who wins on paper.
YSG carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 1.38
- Rev growth 0.8%, EPS growth -2.9%, 3Y rev CAGR -15.8%
- Lower volatility, beta 1.38, Low D/E 4.8%, current ratio 3.67x
SKIN is the clearest fit if your priority is long-term compounding.
- -91.6% 10Y total return vs YSG's -96.8%
- -2.0% margin vs YSG's -11.8%
- -1.2% ROA vs YSG's -12.0%, ROIC -6.8% vs -10.9%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 0.8% revenue growth vs SKIN's -10.0% | |
| Quality / Margins | -2.0% margin vs YSG's -11.8% | |
| Stability / Safety | Beta 1.38 vs SKIN's 2.00, lower leverage | |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | -31.4% vs SKIN's -35.9% | |
| Efficiency (ROA) | -1.2% ROA vs YSG's -12.0%, ROIC -6.8% vs -10.9% |
YSG vs SKIN — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
YSG vs SKIN — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
Evenly matched — YSG and SKIN each lead in 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
YSG is the larger business by revenue, generating $4.1B annually — 13.7x SKIN's $296M. SKIN is the more profitable business, keeping -2.0% of every revenue dollar as net income compared to YSG's -11.8%. On growth, YSG holds the edge at +50.0% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $4.1B | $296M |
| EBITDAEarnings before interest/tax | -$60M | $9M |
| Net IncomeAfter-tax profit | -$479M | -$6M |
| Free Cash FlowCash after capex | $0 | $29M |
| Gross MarginGross profit ÷ Revenue | +78.3% | +64.9% |
| Operating MarginEBIT ÷ Revenue | -3.9% | -3.6% |
| Net MarginNet income ÷ Revenue | -11.8% | -2.0% |
| FCF MarginFCF ÷ Revenue | -8.7% | +9.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | +50.0% | -6.7% |
| EPS Growth (YoY)Latest quarter vs prior year | +40.7% | +38.0% |
Valuation Metrics
SKIN leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
| Metric | ||
|---|---|---|
| Market CapShares × price | $299M | $118M |
| Enterprise ValueMkt cap + debt − cash | $200M | $264M |
| Trailing P/EPrice ÷ TTM EPS | -2.87x | -5.69x |
| Forward P/EPrice ÷ next-FY EPS est. | 5.14x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | 7331.15x |
| Price / SalesMarket cap ÷ Revenue | 0.59x | 0.39x |
| Price / BookPrice ÷ Book value/share | 0.66x | 2.02x |
| Price / FCFMarket cap ÷ FCF | — | 3.17x |
Profitability & Efficiency
SKIN leads this category, winning 5 of 8 comparable metrics.
Profitability & Efficiency
SKIN delivers a -9.4% return on equity — every $100 of shareholder capital generates $-9 in annual profit, vs $-15 for YSG. YSG carries lower financial leverage with a 0.05x debt-to-equity ratio, signaling a more conservative balance sheet compared to SKIN's 6.20x. On the Piotroski fundamental quality scale (0–9), SKIN scores 7/9 vs YSG's 4/9, reflecting strong financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | -15.5% | -9.4% |
| ROA (TTM)Return on assets | -12.0% | -1.2% |
| ROICReturn on invested capital | -10.9% | -6.8% |
| ROCEReturn on capital employed | -11.1% | -4.5% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 7 |
| Debt / EquityFinancial leverage | 0.05x | 6.20x |
| Net DebtTotal debt minus cash | -$668M | $146M |
| Cash & Equiv.Liquid assets | $817M | $233M |
| Total DebtShort + long-term debt | $149M | $379M |
| Interest CoverageEBIT ÷ Interest expense | — | 0.81x |
Total Returns (Dividends Reinvested)
YSG leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in SKIN five years ago would be worth $707 today (with dividends reinvested), compared to $624 for YSG. Over the past 12 months, YSG leads with a -31.4% total return vs SKIN's -35.9%. The 3-year compound annual growth rate (CAGR) favors YSG at -12.7% vs SKIN's -56.4% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | -30.4% | -35.0% |
| 1-Year ReturnPast 12 months | -31.4% | -35.9% |
| 3-Year ReturnCumulative with dividends | -33.6% | -91.7% |
| 5-Year ReturnCumulative with dividends | -93.8% | -92.9% |
| 10-Year ReturnCumulative with dividends | -96.8% | -91.6% |
| CAGR (3Y)Annualised 3-year return | -12.7% | -56.4% |
Risk & Volatility
Evenly matched — YSG and SKIN each lead in 1 of 2 comparable metrics.
Risk & Volatility
YSG is the less volatile stock with a 1.38 beta — it tends to amplify market swings less than SKIN's 2.00 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. SKIN currently trades 33.8% from its 52-week high vs YSG's 25.5% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.38x | 2.00x |
| 52-Week HighHighest price in past year | $11.57 | $2.69 |
| 52-Week LowLowest price in past year | $2.64 | $0.76 |
| % of 52W HighCurrent price vs 52-week peak | +25.5% | +33.8% |
| RSI (14)Momentum oscillator 0–100 | 39.9 | 52.1 |
| Avg Volume (50D)Average daily shares traded | 141K | 760K |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates YSG as "Hold" and SKIN as "Hold".
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Hold |
| Price TargetConsensus 12-month target | — | $1.30 |
| # AnalystsCovering analysts | 3 | 13 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +20.0% | 0.0% |
SKIN leads in 2 of 6 categories (Valuation Metrics, Profitability & Efficiency). YSG leads in 1 (Total Returns). 2 tied.
YSG vs SKIN: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is YSG or SKIN a better buy right now?
For growth investors, Yatsen Holding Limited (YSG) is the stronger pick with 0.
8% revenue growth year-over-year, versus -10. 0% for The Beauty Health Company (SKIN). Analysts rate Yatsen Holding Limited (YSG) a "Hold" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — YSG or SKIN?
Over the past 5 years, The Beauty Health Company (SKIN) delivered a total return of -92.
9%, compared to -93. 8% for Yatsen Holding Limited (YSG). Over 10 years, the gap is even starker: SKIN returned -91. 6% versus YSG's -96. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — YSG or SKIN?
By beta (market sensitivity over 5 years), Yatsen Holding Limited (YSG) is the lower-risk stock at 1.
38β versus The Beauty Health Company's 2. 00β — meaning SKIN is approximately 44% more volatile than YSG relative to the S&P 500. On balance sheet safety, Yatsen Holding Limited (YSG) carries a lower debt/equity ratio of 5% versus 6% for The Beauty Health Company — giving it more financial flexibility in a downturn.
04Which is growing faster — YSG or SKIN?
By revenue growth (latest reported year), Yatsen Holding Limited (YSG) is pulling ahead at 0.
8% versus -10. 0% for The Beauty Health Company (SKIN). On earnings-per-share growth, the picture is similar: The Beauty Health Company grew EPS 55. 6% year-over-year, compared to -2. 9% for Yatsen Holding Limited. Over a 3-year CAGR, SKIN leads at -6. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — YSG or SKIN?
The Beauty Health Company (SKIN) is the more profitable company, earning -3.
2% net margin versus -20. 9% for Yatsen Holding Limited — meaning it keeps -3. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SKIN leads at -6. 9% versus -12. 4% for YSG. At the gross margin level — before operating expenses — YSG leads at 77. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — YSG or SKIN?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is YSG or SKIN better for a retirement portfolio?
For long-horizon retirement investors, Yatsen Holding Limited (YSG) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding.
The Beauty Health Company (SKIN) carries a higher beta of 2. 00 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (YSG: -96. 8%, SKIN: -91. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between YSG and SKIN?
These companies operate in different sectors (YSG (Consumer Cyclical) and SKIN (Consumer Defensive)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.